Submitted Projects:

This project focuses on drug development for Parkinson’s disease (PD), Alzheimer’s disease (AD) and other related diseases such as type 2 diabetes (T2D). The team uses a new drug screening technology to solve the biological stress (Biochemical Stress) problem in these diseases from the fundamental biological mechanism-including Oxidative Stress, Glyoxal Stress and Protein Aggregation stress and many more. Cantabio is now focusing on the development of new drugs in the small molecule chaperone category that will soon enter clinical testing. Cantabio’s core technical advantage in the global sense lies in its research and development capabilities for Intrinsically Disordered Proteins such as Tau and new protein targets such as DJ-1. DJ-1’s multifunctional characteristics have a systemic effect on biological stress.

Company’s candidate medicine Posiphen® targets early stage Parkinson’s Disease as well as Alzheimer’s Disease and may stop or slow the progression of those diseases. Posiphen® reduces levels of amyloid precursor protein (APP), tau and α-Synuclein (aSYN), three proteins that can turn toxic and precipitate the onset of neurodegeneration.

Posiphen® inhibits APP, tau and aSYN in tissue culture cells, mice as well as in humans. Posiphen® also shows promise in Huntington’s disease, Down Syndrome, Traumatic Brain Injury, and Post Operative Cognitive Decline. So far three clinical studies have been conducted with Posiphen®.”

Project is brought by a small asset-centric CNS drug development company based in Cambridge, MA, USA.  The company has raised $4.7M in private financing and been awarded $4M in NIH grants.AST-004 is a novel small molecule A3R agonist that activates mitochondrial energy production in astrocytes and promotes multiple intrinsic neuroprotective mechanisms.